Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D03229 (
BLM
)
1,348
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The ability of a [111In]bleomycin complex [( 111In]BLMC) to kill five cell lines of human lung cancer (small cell lung cancer) was investigated. Cells were exposed to either 0.9% NaCl, [111In]Cl3,
BLM
, [111In]BLMC, nonradioactive
InCl3
, or In-BLMC for 60 minutes, plated in soft agarose, and assessed for colony formation. [111In]BLMC (40-200 microCi carried by 15-25 micrograms
BLM
/ml) was more cytotoxic than
BLM
(15-25 micrograms
BLM
/ml) by a factor of 1.6-5.3 for five cell lines. The percent survival of N417 cells was 28.4 for [111In]BLMC (40 microCi/15 micrograms
BLM
/ml) and 54.3 for
BLM
(15 micrograms/ml); 1.9 for [111In]BLMC (200 microCi/25 micrograms
BLM
/ml), and 10.0 for
BLM
(25 micrograms/ml). 111InCl3 (200 microCi/ml) and nonradioactive
InCl3
failed to inhibit colony formation. The new [111In]BLMC may be useful for therapy of some lung cancer patients.
...
PMID:Killing of human lung cancer cells using a new [111In]bleomycin complex [111In]BLMC. 248 33